Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the safety and efficacy of the PathoLase FootLaser treatment of infected toenails.
The study is a multi-center controlled study evaluating laser treatments of infected great toes in a randomized blinded study of approximately 125 subjects. Right and left great toes are randomized to treatment or no treatment. Samples from infected areas are sampled and evaluated for presence of fungus with KOH, PCR and culture tests. Nail bed clearing and nail plate growth are measured from high resolution photographs by a blinded evaluator. Subjects will be evaluated at baseline and at 8, 16, 24 and 48 weeks for safety and effectiveness of study treatment.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Randomized great toe | Experimental | Subjects with both great toes infected. Right/left randomized to treatment / no treatment |
|
| Untreated Toe | No Intervention |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PinPointe FootLaser | Device | Medical laser |
|
| Measure | Description | Time Frame |
|---|---|---|
| Nail Bed Clearing | Change in amount of clear nail over time. | 48 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Mycology | KOH, PCR and cultures of patients who were bilaterally positive or negative for each test. | 48 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David M Harris, PhD | PathoLase, Inc. | Study Director |
| Bernard Goffe, MD | Dermatology Associates | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rochester Laser Center | Rochester | New York | 14617 | United States | ||
| Endeavor Clinical Trials, PA |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Randomized Great Toe | Subjects with both great toes infected. Right/left randomized to treatment / no treatment |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Randomized Great Toe | Subjects with both great toes infected. Right/left randomized to treatment / no treatment |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Nail Bed Clearing | Change in amount of clear nail over time. | There was a fatal design flaw to the trial. We were advised to collect nail samples for mycologic analysis at every visit. As a result investigators were removing our primary outcome variable, increase in clear nail, at each visit. Consequently our estimates of nail growth following treatment are inaccurate and invalid. | Posted | 48 weeks |
|
48 weeks
Adverse events not assessed for untreated toe. Adverse events are per toe not per patient.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Treated Great Toe | Laser treatment of great toe |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| intraoperative foot pain | Surgical and medical procedures |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| David M Harris, PhD, Research Director | PathoLase | 510-502-3345 | bmcinc@comcast.net |
Not provided
| ID | Term |
|---|---|
| D014009 | Onychomycosis |
| ID | Term |
|---|---|
| D014005 | Tinea |
| D003881 | Dermatomycoses |
| D009181 | Mycoses |
| D001423 | Bacterial Infections and Mycoses |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| San Antonio |
| Texas |
| 78229 |
| United States |
| Dermatology Associates | Seattle | Washington | 98101 | United States |
| Mediprobe Research Inc | London | Ontario | N5X 2P1 | Canada |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Units | Counts |
|---|---|
| Participants |
|
| Secondary | Mycology | KOH, PCR and cultures of patients who were bilaterally positive or negative for each test. | There was a fatal design flaw to the trial. We were advised to collect nail samples for mycologic analysis at every visit. As a result investigators were removing our primary outcome variable, increase in clear nail, at each visit. Consequently our estimates of nail growth following treatment are inaccurate and invalid. | Posted | 48 weeks |
|
|
| 0 |
| 139 |
| 15 |
| 139 |
| EG001 | Untreated Great Toe | untreated control great toe | 0 | 0 | 0 | 0 |
Not provided
Not provided
Not provided
| D007239 |
| Infections |
| D012874 | Skin Diseases, Infectious |
| D009260 | Nail Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |